Abstract: The present invention provides compositions and methods for treating cancer or a metastasis thereof in a subject. In some embodiments, the methods involve administering a composition comprising therapeutically effective amount of at least one immune stimulator to the subject. In some embodiments, a combination of at least two immune stimulators is used for the treatment. In some embodiments, the combination includes an alpha thymosin peptide and an additional immune stimulator, and/or optionally one or more additional anti-cancer agents.
Type:
Application
Filed:
January 7, 2020
Publication date:
September 17, 2020
Inventors:
Robert S. KING, Cynthia W. TUTHILL, Friedhelm BLOBEL
Abstract: Provided herein, in some aspects, are delivery vehicles comprising a glycosphingolipid and an agent to be delivered attached to the glycosphingolipid. In some embodiments, the glycosphingolipid comprises an oligosaccharide and a short chain (e.g., C0-C3) ceramide. In some embodiments, the agent to be delivered is a therapeutic agent. The glycosphingolipid is able to deliver the agent to a cell or to a cellular compartment, as well as across the musical barrier. In some embodiments, agents delivered using the glycosphingolipid described herein exhibit longer half-life, compared to agents delivered alone. Methods of delivering a therapeutic agent to a subject for treating a disease using the glycosphingolipid delivery vehicle are also provided.
Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering therapeutic agents (TA) within the GI tract. Many embodiments provide a swallowable device such as a capsule for delivering TAs into the intestinal wall (IW) or other GI location. Embodiments also provide various TA preparations (e.g., insulin or IgG) configured to be contained within the capsule, advanced from the capsule into the IW and degrade to release the TA into the bloodstream where they exhibit a selected plasma concentration profile which may have selected pharmacokinetic parameters. The preparation can be operably coupled to a delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Type:
Application
Filed:
March 12, 2020
Publication date:
September 17, 2020
Inventors:
Mir Hashim, Radhika Korupolu, Baber Syed, Kyle Horlen, Simret Beraki, Padma Karamchedu, Arvinder Dhalla, Rodolphe Ruffy, April Lynn Toledo, Joel Harris, Mir Imran
Abstract: According to the present invention, a liquid pharmaceutical preparation containing teriparatide or a salt thereof having excellent physical properties, the liquid pharmaceutical preparation containing teriparatide or a salt thereof, and at least one or more members of inorganic salts and/or organic salts is provided.
Abstract: A liquid pharmaceutical preparation for subcutaneous administration in human containing 28.2 ?g of teriparatide or a salt thereof (Component 1) in a unit dose in terms of teriparatide, wherein the Component 1 concentration is from 80 to 240 ?g/mL. This liquid pharmaceutical preparation is excellent in the viewpoint of pharmacokinetics.
Abstract: The present invention relates to the field of nanovectors for the delivery of active substances in the body, in particular for the treatment of tumours. In particular, the use of these nanovectors makes it possible to improve the pharmacokinetics of the active substances with a more selective delivery, for example in the tumour tissues.
Abstract: Disclosed herein are methods and compositions related to coagulation factor complexes comprising a coagulation factor; a fusion protein; and a modifying molecule, wherein the modifying molecule is coupled to the coagulation factor in such a way as to allow binding by the fusion protein, thereby creating a modified coagulation factor; wherein the modilied coagulation factor and the fusion protein interact in at least two independent sites.
Abstract: The present invention provides a method for treating inflammatory conditions, for example, inflammatory bowel disease, ulcerative colitis induced inflammatory bowel disease, spinal cord injury or spaceflight-induced immune dysregulation and associated comorbidities in a mammal or subject in need of such treatment. The present invention also provides a method for decreasing osteocyte protein levels in a mammal suffering from inflammatory condition. A pharmacologically effective does of Irisin or a pharmaceutical composition of irisin is administered to the mammal or subject one or more times.
Type:
Application
Filed:
October 25, 2018
Publication date:
September 17, 2020
Applicant:
Texas A&M University System
Inventors:
Corinne Metzger, Anand Narayanan, David Zawieja, Susan Bloomfield
Abstract: The present disclosure provides compositions and therapies that can address both the symptoms and disorders associated with insufficient surfactant production and hyperoxia. In one embodiment, the composition can be formulated for aerosol delivery during ventilation therapy. The composition can comprise one or more of the following: a PPAR gamma agonist, a surfactant peptide, and one or more phospholipids. The compositions are formulated to provide the complementary benefits of reducing the likelihood of developing or the severity of RDS in infants, as well as protecting and promoting lung maturation in a hyperoxic environment.
Type:
Application
Filed:
March 6, 2017
Publication date:
September 17, 2020
Inventors:
Virender K. REHAN, John S. TORDAY, Frans J. WALTHER, Alan J. WARING, Larry M. GORDON
Abstract: Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
Type:
Application
Filed:
February 5, 2020
Publication date:
September 17, 2020
Applicant:
Denali Therapeutics Inc.
Inventors:
Mark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
Abstract: Compositions and methods for expressing Factor IX in a host cell or a population of host cells are provided. Also provided are engineered host cells expressing Factor IX.
Type:
Application
Filed:
October 18, 2019
Publication date:
September 17, 2020
Inventors:
John Finn, Hon-Ren Huang, Moitri Roy, KehDih Lai, Rachel Sattler, Christos Kyratsous, Cheng Wang
Abstract: Disclosed herein are polynucleotides encoding multi-epitope polypeptides and assemblies thereof, and their use for treating or limiting Toxoplasma gondii infection.
Type:
Application
Filed:
June 3, 2020
Publication date:
September 17, 2020
Inventors:
Rima MCLEOD, Kamal EL BISSATI, Ying ZHOU, Jeff ALEXANDER, Lo VANG, Steve REED, Sara M. PAULILLO, Senthil K. RAMAN, Peter BURKHARD, Mariane MELO, Darrel IRVINE, Ron WEISS, Yuan ZHANG, Alessandro SETTE, John SIDNEY, Brian D. LIVINGSTON, Hernan LORENZI
Abstract: The present invention relates to a cancer-specific tumor antigen neoepitope represented by any one of SEQ ID NOs: 1 to 214, an antigen-presenting cell loaded with the neoepitope, and a method for activating T cells for cancer treatment using the antigen-presenting cell. An antigen-presenting cell, that is, a dendritic cell, loaded with a cancer-specific tumor antigen epitope provided in the present invention enables rapid and effective induction of differentiation and proliferation of cancer antigen-specific T cells, preferably memory T cells, and the memory T cells thus activated can treat a cancerous or neoplastic condition or prevent recurrence, progression, or metastasis of cancer while avoiding the defense mechanism of cancer cells.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
May 29, 2020
Publication date:
September 17, 2020
Inventors:
Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
May 29, 2020
Publication date:
September 17, 2020
Inventors:
Colette SONG, Linus BACKERT, Heiko SCHUSTER, Daniel Johannes KOWALEWSKI, Oliver SCHOOR, Jens FRITSCHE, Toni WEINSCHENK, Harpreet SINGH
Abstract: The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered.
Type:
Application
Filed:
February 20, 2020
Publication date:
September 17, 2020
Applicant:
GeoVax, Inc.
Inventors:
Harriet Robinson, Arban Domi, Michael Hellerstein, Farshad Guirakhoo, Nathanael Paul McCurley
Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.
Type:
Application
Filed:
December 3, 2018
Publication date:
September 17, 2020
Applicant:
Intervet Inc.
Inventors:
Rhonda LaFleur, Jennifer C. Dant, Mark A. Mogler, Steven M. Callister, Zhichang Xu
Abstract: Disclosed herein is a Chlamydia-activated B cell (CAB) platform. Also disclosed is a method of enhancing a population of B cells, comprising exposing said B cells to Chlamydia spp. under conditions suitable to enhance the population of B cells, such that expansion and differentiation of said B cells takes place, and said B cells are exposed or crosslinked to an antigen. Also disclosed are methods of producing said CABs, and treating a subject in need thereof with said CABs.
Abstract: The data reported herein describe the production and evaluation of a recombinant subunit filovirus vaccine using insect cell expressed surface glycoprotein (GP) and a highly effective adjuvant. The vaccine provides protection in humans against filovirus infection, including Ebola virus and Marburg virus.
Type:
Application
Filed:
September 6, 2018
Publication date:
September 17, 2020
Inventors:
David E. CLEMENTS, Michael M. LIEBERMAN, Axel T. LEHRER
Abstract: The present invention is directed to a method of booster vaccination and to a vaccine composition for use in such a method, for inducing in a human subject a neutralizing antibody response, wherein said subject has previously received a primary vaccination against each of serotypes 1 to 4 of dengue virus and was dengue naïve before said primary vaccination, said composition comprising a dengue antigen of at least one of serotypes 1 to 4 or a nucleic acid construct capable of expressing said antigens in the subject, wherein said booster vaccination results in a 2-fold increase in the neutralizing antibody titre against each of serotypes 1 to 4.
Type:
Application
Filed:
October 5, 2018
Publication date:
September 17, 2020
Inventors:
Diana Coronel, Betzana Zambrano, Fernando Noriega, Tram Anh Wartel
Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
Type:
Application
Filed:
April 16, 2020
Publication date:
September 17, 2020
Applicant:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
Abstract: The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof. The invention includes ribonucleic acid vaccines and combination vaccines, as well as methods of using the vaccines and compositions comprising the vaccines for treating and preventing tropical disease.
Type:
Application
Filed:
April 21, 2020
Publication date:
September 17, 2020
Applicant:
ModernaTX, Inc.
Inventors:
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
Abstract: Provided is a swine fever antigen fused with a porcine Fc fragment, and more particularly, to a vaccine composition having an autoimmune-enhancing effect by binding the Fc fragment to a swine fever antigen, and a preparation method thereof.
Type:
Application
Filed:
September 16, 2019
Publication date:
September 17, 2020
Applicants:
BIOAPPLICATIONS INC., REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
Inventors:
Yongjik LEE, Dong-Jun AN, Se Eun CHOE, Jae-Young SONG, In-Soo CHO
Abstract: The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen. Specifically, the present invention relates compositions suitable for immunotherapy comprising an allergen, wherein substantially 100% of said allergen in said composition is complexed with aluminum.
Type:
Application
Filed:
June 3, 2020
Publication date:
September 17, 2020
Inventors:
Joanna Paulina Maria van der Kleij, Dirk Jan Elbertus Opstelten
Abstract: A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder, white nose syndrome, etc. and in particular, provides honey bees, bats and butterflies with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.
Abstract: The present invention includes composition and methods for composition for the oral delivery of a therapeutic agent that reduces, desensitizes, or prevents food, respiratory and other allergies. First pollen is cleaned to remove naturally-occurring allergic plant proteins to form a cleaned pollen and a therapeutically effective amount of an allergen is introduced into the cleaned pollen. The allergen-loaded cleaned pollen is delivered to a subject in need of therapy.
Abstract: The present invention relates to methods of treating hypertension in a subject in need of treatment thereof, with the methods comprising administering a pharmaceutically effective amount of an angiotensin II inhibitor and a pharmaceutically effective amount of a receptor tyrosine kinase inhibitor to the subject.
Abstract: Disclosed herein are MSLN binding proteins with improved binding affinities and improved ability to mediate T cell dependent killing of cancer cells expressing mesothelin. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
Type:
Application
Filed:
January 27, 2020
Publication date:
September 17, 2020
Inventors:
Holger WESCHE, Bryan D. LEMON, Richard J. AUSTIN, Robert B. DUBRIDGE
Abstract: The present disclosure provides methods comprising administering to the individual an effective amount of an agent that decreases or inhibits TIGIT expression and/or activity and an anti-cancer agent and/or an anti-cancer therapy. Further provided are kits comprising an anti-cancer agent, an agent that decreases or inhibits TIGIT expression and/or activity, or both, as well as instructions for use thereof.
Abstract: The present disclosure relates to a complex having a core-shell structure, a composition and a textile comprising the same, and a method for treating thrombosis, cancer, or wounds using the same. The complex having the core-shell structure comprises a core; and a shell layer covering a surface of the core; wherein the core is made of polypyrrole.
Abstract: The present application relates generally to a method and a composition matter that provides a rapid and potent antimicrobial photodynamic inactivation (aPDI) of pathogenic bacteria that express high-affinity cell-surface hemin receptors (CSHRs) using Ga(III)-protoporphyrins IX (GaPpIX or Ga-PpIX). The invention provides an effective treatment option for infections of skin or body cavities that are accessible to visible-light irradiation, such as a handheld LED array emitting visible light (405 nm), especially for infections caused by Staphylococcus aureus, Methicillin-resistant Staphylococcus aureus (MRSA), pathogenic staphylococci, Streptococcus mutans, S. pneumoniae, S. pyogenes, streptococci, corynebacteria, mycobacteria, and Bacillus anthracis.
Type:
Application
Filed:
May 29, 2020
Publication date:
September 17, 2020
Applicant:
Purdue Research Foundation
Inventors:
Alexander Wei, Ana Victoria Morales-de-Echegaray
Abstract: This invention relates to aqueous pharmaceutical formulations comprising a glucocorticoid. These have been formulated to contain high concentrations of glucocorticoid and reduced levels of preservatives.
Abstract: The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
Abstract: Described herein are methods of syntheses and therapeutic uses of covalently modified peptides and/or proteins. The covalently modified peptides and/or proteins allow for improved pharmaceutical properties of peptide and protein-based therapeutics.
Abstract: A therapeutic method and composition which includes a cannabinoid chemically linked to a chemotherapy agent. The therapeutic composition is capable of crossing the blood-brain barrier, and delivery of the composition across the blood-brain barrier provides both chemotherapy for the treatment of brain cancer and alleviation of side effects caused by the chemotherapy agent. Once across the blood-brain barrier, the chemotherapy agent will be released to attack cancer cells, and the cannabinoid will be free to bind to cannabinoid receptors in the brain to alleviate side effects of chemotherapy such as nausea/vomiting, pain and decreased appetite.
Abstract: The disclosure discloses a linker compound, a polyethylene glycol-linker conjugate and a derivative thereof, and a polyethylene glycol-linker-drug conjugate. The linker compound as well as the conjugate thereof with the polyethylene glycol and the derivative thereof may be used for modifying a drug, and a modification reaction is simple and easy to carry out. Moreover, a reaction yield is high, and an application range of the modified drug is wide. The modified drugs gradually degrade from a chain of the conjugate in vivo, and may stay in a lesion (such as a cancer site) for a longer period of time, achieving purposes of sustained and controlled release, reducing an administration frequency, and greatly improving a bioavailability of the drug and a patient compliance.
Type:
Application
Filed:
March 30, 2020
Publication date:
September 17, 2020
Inventors:
Zewang FENG, Qingbin WANG, Jinliang WANG, Yanping SONG, Yanli XIONG, Leimin WANG, Jinghui DU, Xuan ZHAO
Abstract: A biodegradable polyethylene glycol derivative in which a polyethylene glycol chain is linked by an acetal linker capable of accurately controlling the hydrolysis rate under different pH environments in the living body, and whose division rate into a polyethylene glycol chain of low molecular weight in the living body can be accurately controlled. The biodegradable polyethylene glycol derivative is represented by formula (1) or formula (2) as described.
Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of membrane type 1 metalloprotease (MT1-MMP). The invention also describes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups which have utility in imaging and targeted cancer therapy.
Type:
Application
Filed:
April 2, 2020
Publication date:
September 17, 2020
Inventors:
Daniel Paul Teufel, Catherine Lucy STACE, Silvia PAVAN, Edward WALKER, Leonardo BALDASSARRE
Abstract: Described herein are polyhedral, three-dimensional tunable nanocages assembled with a multimeric protein covalently linked to a polynucleotide handle and a DNA origami base assembly including sequences complementary to the polynucleotide handles, wherein the polynucleotide handle and the complementary sequences hybridize to for double-stranded DNA helices.
Type:
Application
Filed:
March 11, 2020
Publication date:
September 17, 2020
Applicant:
Arizona Board of Regents on Behalf of Arizona State University
Abstract: The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and conjugates thereof. The present disclosure also relates to pharmaceutical compositions of the conjugates described herein, methods of making and methods of using the same.
Type:
Application
Filed:
March 20, 2020
Publication date:
September 17, 2020
Inventors:
Iontcho Radoslavov Vlahov, Christopher Paul Leamon, Longwu QI, Yingcai Wang, Kevin Yu Wang, Ning Zou, Albert E. Felten
Abstract: The invention provides protein-active agent conjugates having an amino acid motif that can be recognized by an isoprenoid transferase. The invention also provides compositions containing the conjugates. The invention further provides methods for using the conjugates to deliver the active agent to a target cell, as well as methods for using the conjugates to treat a subject in need thereof (e.g.
Type:
Application
Filed:
March 9, 2020
Publication date:
September 17, 2020
Inventors:
YongZu Kim, Taekyo Park, Sungho Woo, Hyangsook Lee, Sunyoung Kim, Jongun Cho, Doohwan Jung, Youngun Kim, Hyunjin Kwon, Kyuman Oh, Yunseo Chung, Yun-Hee Park
Abstract: The present invention relates to the use of an anti-HER2 antibody-drug conjugate (ADC) in preparing a drug for treating urothelial carcinoma. The drug is safe and effective for patients with urothelial carcinoma, especially locally advanced or metastatic urothelial carcinoma, and can effectively prolong the survival time of the patients.
Abstract: The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.
Type:
Application
Filed:
January 21, 2020
Publication date:
September 17, 2020
Inventors:
Adam Hartigan, Anthony Boitano, Michael Cooke, Megan D. Hoban, Rahul Palchaudhuri
Abstract: The presently disclosed subject matter provides a biomimetic particle platform that can be used to simulate natural cells found throughout the body. The particle comprises a polymeric core of defined shape, size, and mechanical properties and a surface comprising naturally derived cell membranes, such as red blood cells or platelets. Together these features enable a level of biomimicry that can be appropriated for various drug delivery applications and cell engineering applications.
Type:
Application
Filed:
March 28, 2017
Publication date:
September 17, 2020
Inventors:
JORDAN J. GREEN, RANDALL A. MEYER, ELANA BEN-AKIVA
Abstract: Compositions comprising a macrophage-targeted carrier and one or more therapeutic agents that modulate cardiac conductance, and methods of using the same for treating subjects with cardiac rhythm disorders, e.g., bradycardia or tachycardia.
Type:
Application
Filed:
June 1, 2020
Publication date:
September 17, 2020
Inventors:
Maarten Hulsmans, Matthias Nahrendorf, Ralph Weissleder